The ranking

No public survey ranks pharma functions by total effort, so we combined cost, time, and volume data into our own ranking:

RankWorkloadWhy it is heavyKey figure
1Clinical developmentThe largest cost and the longest timeline; protocols keep getting more complexA Phase III trial costs about $55,700 a day in direct costs (Tufts CSDD)
2Regulatory submissions and lifecycleEvery approval is followed by years of supplements, annual reports, and labeling updatesFDA’s drug center received 319,828 electronic submissions in 2025, up from 139,322 in 2014
3PharmacovigilanceAdverse event volume keeps rising, and each case must be processed on deadlineFDA received about 2.2 million electronic adverse event submissions in 2025
4Quality and GMP complianceProcedures, investigations, and records must be right every timeNot following written procedures was the top FDA Form 483 citation in FY2024 (184 times)
5Commercial and medical content reviewHigh volumes of promotional and medical material need medical, legal, and regulatory reviewMcKinsey puts the largest generative AI value in commercial work ($18 to 30 billion a year)

The common thread is documents: protocols, clinical study reports, submissions, case reports, batch records, and promotional materials. Most of the effort goes into writing, checking, and cross-referencing them.

1. Clinical development: the biggest load

Cost and time.

MeasureFigureSource
Average cost per asset (top 20 pharma)about $2.23 billionDeloitte, 2025
Phase I to filingabout 100 months, up from 93 in 2020Deloitte, 2025
Phase I start to approval9.3 years in 2024IQVIA, 2025
Direct trial cost per dayPhase III $55,716; Phase II $23,737; Phase I $7,829Tufts CSDD (2023 dollars)
Lost sales per day of delayabout $800,000Tufts CSDD
US site-based trial spending, 2023$30.6 billion; $24,000 to $282,000 per participantTEConomy for PhRMA
Trials on assets later terminated, 2024about $7.7 billionDeloitte, 2025

Complexity keeps rising.

  • Compared with 10 years ago, protocols have 29% more endpoints and 61% more procedures (Tufts/SCRS, 2026).
  • The average Phase III protocol has 301 procedures, up from 187.
  • Deviations per pivotal trial have more than doubled.
  • A Phase III protocol now collects nearly 6 million data points, growing about 11% a year. About a third of the procedures and data points are not core to the main endpoints (Tufts/TransCelerate).

Amendments add cost. Older Tufts data (2016) found:

  • 57% of protocols had at least one substantial amendment.
  • Each cost a median $535,000 in Phase III.
  • About half were avoidable.

Documents are a big part of the load. Writing a clinical study report (CSR) typically takes more than 8 weeks (McKinsey). Merck reported cutting first-draft effort from 180 hours to 80 with generative AI.

2. Regulatory submissions and lifecycle

The workload does not end at approval:

  • FDA’s drug center received 319,828 electronic submissions in 2025, more than twice the 2014 level (139,322). FDA’s biologics center received 97,133.
  • FDA’s own paperwork estimate for 21 CFR 314 (2023):
    • a new drug application (NDA) takes about 1,921 hours to prepare, across about 121 NDAs a year
    • about 2,570 supplements a year take about 150 hours each
    • about 3,090 annual reports take about 40 hours each
    • in total, about 3.5 million hours a year
  • An older industry report (2020) found that large companies each employ more than 2,000 people to keep product information current with regulators.

3. Pharmacovigilance

  • FDA received 2,203,397 electronic adverse event submissions in 2025, compared with 1,026,314 in 2014.
  • In Deloitte’s 2019 survey, case processing took 40 to 85% of pharmacovigilance budgets, and case volumes grew 10 to 15% a year.
  • Productivity ranged from 300 to 400 case reports per full-time employee, up to 1,000 to 2,000 at scale.

4. Quality and GMP

In FY2024, FDA issued 561 Form 483s to drug manufacturers. The most cited problems were about procedures and investigations:

FY2024 citationCount
Written procedures not followed (21 CFR 211.22(d))184
Discrepancies not investigated (211.192)116
Procedures missing (211.100(a))109
Lab controls not scientifically sound (211.160(b))109

FDA’s FY2024 pharmaceutical quality report counted 105 quality warning letters, the most in five years, and 421 recalled products. Seventeen percent of drug Form 483s cited the stability program. The burden is ongoing documentation and investigation, not one-off fixes.

5. Where AI and automation help

McKinsey (2024) estimates generative AI’s annual value in pharma at $60 to 110 billion:

AreaEstimated annual value
Commercial$18 to 30 billion
Research$15 to 28 billion
Clinical development$13 to 25 billion
Operations$4 to 7 billion
Medical affairs$3 to 5 billion

The parts add up to less than the headline range, and McKinsey does not explain the gap.

Task-level examples:

  • Medical writing: costs could fall 20 to 30% now, and 50 to 70% as tools mature.
  • Regulatory submissions: could be about 40% faster.
  • Merck’s clinical study reports: time to completion fell from 2 to 3 weeks to 3 to 4 days, and errors fell by half.

The heaviest workloads are the best targets because they are document-heavy and rule-based. AI drafts, checks, and cross-references; people stay accountable for decisions.

Using this in AI and RAG

  1. Index the rules behind each workload: ICH guidelines, 21 CFR 312 and 314, pharmacovigilance and GMP regulations.
  2. Index your own documents by workload: protocols, clinical study reports, submissions, case reports, deviations.
  3. Measure before and after: hours per document, error rates, cycle times.
  4. Keep humans signing off on clinical, safety, and quality decisions.

Common mistakes

  • Automating low-volume tasks while the heavy document work stays manual.
  • Ignoring protocol design, where a third of the data collected is not core.
  • Treating AI drafts as final without review.
  • Measuring adoption instead of time saved.

Checklist

  • Workloads ranked by hours and cost in your own company
  • Rules and internal documents indexed per workload
  • Baseline metrics captured
  • Human sign-off defined

How AskDona helps

AskDona targets the document-heavy part of these workloads. It checks protocols, clinical study reports, submission sections, safety narratives, and deviation reports against the rules and your own source documents, and cites the passage behind each finding.

Run a sample document evidence check

AskDona shows the evidence; your clinical, regulatory, safety, and quality teams decide.

Editor’s note. This article is general information. The ranking is our editorial judgment based on the cited data, because no public source ranks pharma functions by total effort. Some figures (amendment costs from 2016, pharmacovigilance budgets from 2019) are older and marked as such.

FAQ

What is the most expensive workload in pharma? Clinical development. A Phase III trial costs about $55,700 a day in direct costs, and an asset averages about $2.23 billion to develop.

How many submissions does FDA receive for drugs? CDER received 319,828 electronic submissions in 2025.

How many adverse event reports does FDA receive? About 2.2 million electronic submissions in 2025.

What is the most common FDA GMP finding? Not following written procedures, cited 184 times in FY2024.

References

All pages opened and checked by October 30, 2026.

SourceWhat it supports
BioSpace: Deloitte pharma R&D returns (Mar 2025)Cost per asset, cycle time, terminated trials
IQVIA: Global Trends in R&D 20259.3 years to approval
Tufts CSDD: Day of Delay white paper (PDF)Daily trial cost, lost sales per day
TEConomy for PhRMA (PDF)US trial spending, cost per participant
Clinical Leader: Protocol complexity (Jan 2026)Endpoints, procedures, deviations
MedCity News: Protocol complexity (Apr 2026)6 million data points, non-core share
Applied Clinical Trials: Protocol amendmentsAmendment frequency and cost (2016)
FDA: ESG submission statisticsCDER, CBER, AERS submissions
Federal Register: 21 CFR 314 burden estimate (2023)NDA, supplement, annual report hours
IQVIA/EPR: Regulatory affairs and automation (PDF, 2020)2,000+ staff on product information
Deloitte: Transforming pharmacovigilance (PDF)Case processing share, volumes, productivity
RAPS: Top GMP violations (Mar 2026)FY2024 Form 483 citations
ECA: Stability 483s FY2024561 Form 483s, 17% stability
FDA Law Blog: FY2024 pharmaceutical quality reportWarning letters, recalls, inspections
McKinsey: Gen AI in pharma (2024)Value by function, CSR time
McKinsey: Merck clinical authoring (Jun 2025)CSR hours and errors